Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Neurol Sci ; 41(2): 451-455, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31506829

ABSTRACT

Alzheimer's disease (AD) is the most incident neurodegenerative disorder, characterized by accumulation of extracellular amyloid-ß (Aß), intracellular neurofibrillary tangles, and cognitive impairment. The current available treatments are mainly based on the use of reversible acetylcholinesterase (AChE) inhibitors, which only ameliorate the cognitive deficits. However, it is important to develop disease-modifying drugs with neuroprotective effects in order to hamper the progression of the disease. Here, we describe the effect of four promising new drugs with additional protective characteristics on AD-associated memory changes. C57Bl/6 mice treated with the compounds received an intra-hippocampal injection of Aß1-40 and were submitted to the novel object recognition test, to evaluate memory recovery. All the compounds prevented memory loss. Compounds PQM-56 (4c) and PQM-67 (4g) showed the best profile of memory recovery, representing potential drug candidates for AD treatment.


Subject(s)
Alzheimer Disease/drug therapy , Cholinesterase Inhibitors/pharmacology , Memory Disorders/drug therapy , Memory/drug effects , Amyloid beta-Peptides/metabolism , Animals , Cognition Disorders/drug therapy , Disease Models, Animal , Memory Disorders/chemically induced , Mice, Inbred C57BL , Neuroprotective Agents/therapeutic use , Peptide Fragments/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...